Literature DB >> 17294241

Comprehensive analysis of 130 multicentric intraepithelial female lower genital tract lesions by HPV typing and p16 expression profile.

Monika Hampl1, Nicolas Wentzensen, Svetlana Vinokurova, Magnus von Knebel-Doeberitz, Cristopher Poremba, Hans G Bender, Volkmar Kueppers.   

Abstract

PURPOSE: HPV associated cervical transformation is characterized by well-defined steps, including persistent HPV infection and deregulated oncogene expression. Recent studies have suggested that a number of lower genital tract lesions are clonally related to cervical lesions. In the current study, HPV infections and oncogene expression were assessed in a large series of patients with multicentric lower genital tract disease to analyze the transformation steps in extracervical disease.
METHODS: One hundred and thirty biopsies of 52 women treated for multicentric synchronous or metachronous lower genital tract intraepithelial neoplasias were collected. Up to seven multicentric specimens taken from one patient were studied with a maximum follow up of 20 years. HPV typing and p16(ink4a) immunostaining was performed.
RESULTS: HPV DNA was present in 121 of 130 specimens (93%). HPV16 was frequently found in VIN, VaIN and AIN (73, 60 and 77%, respectively), whereas only 37% of CIN were HPV16 positive. Infections with identical HPV types in multicentric lesions were diagnosed in 46% of the HPV positive patients. p16INK4a expression was negative in the nine HPV negative lesions whereas about 90% of the high grade lesions showed diffuse p16 staining.
CONCLUSION: Our findings indicate that multicentric lower genital tract disease evolves through different pathways. Some cases were related to a high susceptibility towards HPV infections, while others exhibited features of clonal propagation of transformed cervical cell clones. The clinical management of the latter group is particularly challenging, because malignant cell clones can persist over a long time course.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17294241     DOI: 10.1007/s00432-006-0162-0

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  41 in total

1.  Trends in the incidence of invasive and in situ vulvar carcinoma.

Authors:  Patricia L Judson; Elizabeth B Habermann; Nancy N Baxter; Sara B Durham; Beth A Virnig
Journal:  Obstet Gynecol       Date:  2006-05       Impact factor: 7.661

2.  Human papillomavirus typing and DNA ploidy determination of squamous intraepithelial lesions in liquid-based cytologic samples.

Authors:  Reinhard Bollmann; Gábor Méhes; Robert Torka; Norbert Speich; Christoph Schmitt; Magdolna Bollmann
Journal:  Cancer       Date:  2003-02-25       Impact factor: 6.860

3.  Human papillomavirus type 16 infections and 2-year absolute risk of cervical precancer in women with equivocal or mild cytologic abnormalities.

Authors:  Philip E Castle; Diane Solomon; Mark Schiffman; Cosette M Wheeler
Journal:  J Natl Cancer Inst       Date:  2005-07-20       Impact factor: 13.506

4.  Predictive significance of the alterations of p16INK4A, p14ARF, p53, and proliferating cell nuclear antigen expression in the progression of cervical cancer.

Authors:  Jian-Liu Wang; Bi-Ying Zheng; Xi-Dan Li; Tord Angström; Mikael S Lindström; Keng-Ling Wallin
Journal:  Clin Cancer Res       Date:  2004-04-01       Impact factor: 12.531

Review 5.  New markers for cervical dysplasia to visualise the genomic chaos created by aberrant oncogenic papillomavirus infections.

Authors:  M von Knebel Doeberitz
Journal:  Eur J Cancer       Date:  2002-11       Impact factor: 9.162

6.  A cohort study of the risk of cervical intraepithelial neoplasia grade 2 or 3 in relation to papillomavirus infection.

Authors:  L A Koutsky; K K Holmes; C W Critchlow; C E Stevens; J Paavonen; A M Beckmann; T A DeRouen; D A Galloway; D Vernon; N B Kiviat
Journal:  N Engl J Med       Date:  1992-10-29       Impact factor: 91.245

7.  Vulvar intraepithelial neoplasia of the simplex (differentiated) type: a clinicopathologic study including analysis of HPV and p53 expression.

Authors:  B Yang; W R Hart
Journal:  Am J Surg Pathol       Date:  2000-03       Impact factor: 6.394

8.  Human papillomavirus is associated with the frequent detection of warty and basaloid high-grade neoplasia of the vulva and cervical neoplasia among immunocompromised women.

Authors:  K U Petry; H Köchel; U Bode; I Schedel; S Niesert; M Glaubitz; H Maschek; H Kühnle
Journal:  Gynecol Oncol       Date:  1996-01       Impact factor: 5.482

Review 9.  Intraepithelial neoplasia of the vulva.

Authors:  R H Kaufman
Journal:  Gynecol Oncol       Date:  1995-01       Impact factor: 5.482

10.  Validation of p16INK4a as a marker of oncogenic human papillomavirus infection in cervical biopsies from a population-based cohort in Costa Rica.

Authors:  Sophia S Wang; Marcus Trunk; Mark Schiffman; Rolando Herrero; Mark E Sherman; Robert D Burk; Allan Hildesheim; M Concepcion Bratti; Tom Wright; Ana Cecilia Rodriguez; Sabrina Chen; Anja Reichert; Christina von Knebel Doeberitz; Ruediger Ridder; Magnus von Knebel Doeberitz
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2004-08       Impact factor: 4.254

View more
  18 in total

Review 1.  [Nomenclature of squamous cell precursor lesions of the lower female genital tract : Current aspects].

Authors:  L-C Horn; C E Brambs; R Handzel; G Mehlhorn; D Schmidt; K Schierle
Journal:  Pathologe       Date:  2016-11       Impact factor: 1.011

Review 2.  [HPV-associated alterations of the vulva and vagina. Morphology and molecular pathology].

Authors:  L-C Horn; K Klostermann; S Hautmann; A K Höhn; M W Beckmann; G Mehlhorn
Journal:  Pathologe       Date:  2011-11       Impact factor: 1.011

Review 3.  [HPV-associated head and neck cancer. The basics of molecular and translational research].

Authors:  C Wittekindt; S Wagner; J P Klussmann
Journal:  HNO       Date:  2011-09       Impact factor: 1.284

Review 4.  [Interdisciplinary S2k guidelines on the diagnosis and treatment of vaginal carcinoma and its precursors-recommendations on surgical pathology for histopathological workup, diagnostics, and reporting].

Authors:  Lars-Christian Horn; Anne Kathrin Höhn; Monika Hampl; Grit Mehlhorn; Markus Follmann; Hans-Georg Schnürch
Journal:  Pathologe       Date:  2021-02       Impact factor: 1.011

5.  Human papilloma virus early proteins E6 (HPV16/18-E6) and the cell cycle marker P16 (INK4a) are useful prognostic markers in uterine cervical carcinomas in Qassim Region--Saudi Arabia.

Authors:  O M Omran; M AlSheeha
Journal:  Pathol Oncol Res       Date:  2014-06-13       Impact factor: 3.201

6.  Molecular etiology of second primary tumors in contralateral tonsils of human papillomavirus-associated index tonsillar carcinomas.

Authors:  Andrew W Joseph; Takenori Ogawa; Justin A Bishop; Sofia Lyford-Pike; Xiaofei Chang; Timothy H Phelps; William H Westra; Sara I Pai
Journal:  Oral Oncol       Date:  2012-10-10       Impact factor: 5.337

Review 7.  HPV prophylactic vaccines and the potential prevention of noncervical cancers in both men and women.

Authors:  Maura L Gillison; Anil K Chaturvedi; Douglas R Lowy
Journal:  Cancer       Date:  2008-11-15       Impact factor: 6.860

Review 8.  Human papillomavirus infection and the primary and secondary prevention of cervical cancer.

Authors:  Douglas R Lowy; Diane Solomon; Allan Hildesheim; John T Schiller; Mark Schiffman
Journal:  Cancer       Date:  2008-10-01       Impact factor: 6.860

9.  [Pathoanatomical preparation and reporting of specimens from precancerous lesions and carcinomas of the vulva].

Authors:  L-C Horn; K Schierle; K Klostermann; H-G Schnürch; P Hantschmann
Journal:  Pathologe       Date:  2009-02       Impact factor: 1.011

10.  Patients with usual vulvar intraepithelial neoplasia-related vulvar cancer have an increased risk of cervical abnormalities.

Authors:  R P de Bie; H P van de Nieuwenhof; R L M Bekkers; W J G Melchers; A G Siebers; J Bulten; L F A G Massuger; J A de Hullu
Journal:  Br J Cancer       Date:  2009-06-09       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.